surveillance given the variable "risks"? 
HIMA reconnsends that without any defined hazard or end point, any 
suggestions for blanket medical surveillance of the biotechnology 
Industry is simply not justified. Singling out Biotechnology is 
completely unwarrented and without merit. 
HIMA recognizes the roles that NIOSH and CDC are expected to play, but 
simply does not agree with the proposal's conclusion that blanket 
medical surveillance of the biotechnology Industry Is advisable. 
4 
[5291 
